New Triple-Threat attack on advanced liver cancer before surgery
NCT ID NCT06349317
Summary
This study is testing a three-part treatment given before surgery for a serious form of liver cancer that has grown into a major blood vessel. The goal is to see if combining targeted radiation, an immunotherapy drug (camrelizumab), and a drug that blocks tumor blood supply (apatinib) can better control the cancer and improve outcomes. The study will enroll about 33 patients to measure how long they live without the cancer getting worse after this combined approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mengchao Hepatobiliary Hospital, Fujian Medical University
RECRUITINGFuzhou, Fujian, China
Contact
Conditions
Explore the condition pages connected to this study.